Quick Answer
Trevi Therapeutics, Inc. reported R&D Expense of $33.48 million for fiscal year 2025.
Trevi Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $33.48M | -15.0% |
| 2024 | $39.38M | +66.3% |
| 2023 | $23.68M | +19.4% |
| 2022 | $19.83M | -13.7% |
| 2021 | $22.98M | +2.9% |
| 2020 | $22.33M | +15.5% |
| 2019 | $19.34M | +37.4% |
| 2018 | $14.07M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.09M | -10.1% | +7.4% |
| June 30, 2025 | $9.39M | -6.3% | +20.2% |
| March 31, 2025 | $7.81M | -11.3% | -30.4% |
| September 30, 2024 | $11.22M | +77.5% | +12.0% |
| June 30, 2024 | $10.02M | +71.5% | +13.8% |
| March 31, 2024 | $8.80M | +76.1% | +39.2% |
| September 30, 2023 | $6.32M | +9.6% | +8.2% |
| June 30, 2023 | $5.84M | +14.5% | +16.8% |
- Trevi Therapeutics, Inc. showed a decrease of -15.0% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Trevi Therapeutics, Inc.’s r&d expense has grown by 137.9% (from $14.07 million to $33.48 million).
- The most recent figure is from Trevi Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: